Evidence map›Paper›PMID 41554715›Full record

ArticleNature communications2026

The ratio of circulatory levels of sphingolipids to steroids predicts asthma exacerbations.

Yulu Chen, Pei Zhang, Mengna Huang, Priyadarishini Kachroo, Antonio Checa, Qingwen Chen, Kevin Mendez, Meryl Stav, Nicole Prince, Sofina Begum and 12 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Yulu Chen *Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Pei Zhang *Unit of Integrative Metabolomics, Institute of Environmental Medicine, Karolinska Institute, Stockholm, Sweden.
Mengna HuangChanning Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Priyadarishini KachrooChanning Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0002-5807-1333
Antonio ChecaUnit of Integrative Metabolomics, Institute of Environmental Medicine, Karolinska Institute, Stockholm, Sweden.
Qingwen ChenChanning Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0002-2946-4947
Kevin MendezChanning Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0002-8832-2607
Meryl StavChanning Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0001-6565-3617
Nicole PrinceChanning Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0002-8506-1122
Sofina BegumChanning Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Andrea AparicioChanning Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Tao GuoChanning Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0009-0005-8960-9203
Rinku SharmaChanning Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0003-3036-2080
Su H ChuChanning Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Rachel S KellyChanning Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0003-3023-1822
Julian HeckerChanning Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Ayobami AkenroyeDivision of Allergy and Clinical Immunology, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0002-1909-1470
Amber DahlinChanning Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Scott T WeissChanning Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Michael McGeachieChanning Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0001-5566-2712
Craig E WheelockUnit of Integrative Metabolomics, Institute of Environmental Medicine, Karolinska Institute, Stockholm, Sweden. craig.wheelock@ki.se.ORCID http://orcid.org/0000-0002-8113-0653
Jessica A Lasky-SuChanning Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA. rejas@channing.harvard.edu.ORCID http://orcid.org/0000-0001-6236-4705

Funding

Finding Genomic Profiles of COVID-19 Phenotypes from the EHRU01HG008685 · NHGRI · BRIGHAM AND WOMEN'S HOSPITAL · PI ELIZABETH W KARLSON, Matthew S Lebo · 2015 to 2026
$13.6M
Systems Biology of Airway DiseaseP01HL132825 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI RABY, BENJAMIN ALEXANDER · 2016 to 2020
$12.6M
Proteomics and Metabolomics Core: IDEAL shapes vaccine response, susceptibility to respiratory infectious disease and asthmaU19AI168643 · NIAID · BOSTON CHILDREN'S HOSPITAL · PI OFER LEVY · 2022 to 2026
$10.0M
Integrative Metabolomics of Asthma SeverityR01HL123915 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI LASKY-SU, JESSICA A · 2014 to 2023
$7.0M
Omic Determinants of Longitudinal Lung Function in AsthmaR01HL155742 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI LASKY-SU, JESSICA A, MCGEACHIE, MICHAEL JOHN · 2021 to 2025
$3.9M
Mechanistic insights into asthma pathogenesis through the integration of asthma genes, risk exposures, and metabolomicsR01HL141826 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI LASKY-SU, JESSICA A · 2018 to 2021
$3.4M
Better utilization of omics data to inform precision medicine for asthma throughout the life courseR01HL169300 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI JESSICA A LASKY-SU · 2024 to 2026
$2.3M
Integrative metabolomic characterization of ADHD and asthma comorbidityK01HL153941 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI CHU, SU HEE · 2020 to 2024
$891k
Multi-Omic Endotyping of AsthmaK01HL146980 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI KELLY, RACHEL SABINE · 2019 to 2023
$891k
Methylomic and metabolomic determinants of Lung Function in AsthmaticsR00HL159234 · NHLBI · RUTGERS BIOMEDICAL AND HEALTH SCIENCES · PI Priyadarshini Kachroo · 2024 to 2026
$840k
Methylomic and metabolomic determinants of Lung Function in AsthmaticsK99HL159234 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI KACHROO, PRIYADARSHINI · 2022 to 2023
$346k
Characterizing Biological Aging for Heart and Lung Diseases Using Multi-omics AgeotypesK01HL179256 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI CHEN, YULU · 2025 to 2025
$177k
NHGRI NIH HHS U01 HG008685NHLBI NIH HHS K01 HL146980NHLBI NIH HHS K01 HL153941NHLBI NIH HHS K01 HL179256NHLBI NIH HHS K99 HL159234NHLBI NIH HHS P01 HL132825NHLBI NIH HHS R00 HL159234NHLBI NIH HHS R01 HL123915NHLBI NIH HHS R01 HL141826NHLBI NIH HHS R01 HL155742NHLBI NIH HHS R01 HL169300NIAID NIH HHS U19 AI168643U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (NHLBI) R01HL123915U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (NHLBI) R01HL155742
6 · The paper itself

Abstract

The lack of biomarkers to identify individuals at risk of asthma exacerbations remains a significant limitation to improving patient outcomes. To address this need, we analyze data from three asthma cohorts, combining up to 25 years of electronic medical records with sequential metabolomics studies, to develop and replicate a predictive model for asthma exacerbation risk. We identify asthma-associated biochemical pathways via global circulatory metabolomics and then apply targeted mass spectrometry methods to quantify selected steroids, sphingolipids, and microbial-derived metabolites. The sphingolipid-to-steroid ratios robustly associate with 5-year exacerbation risk (discovery p value = 1.63×10⁻

Indexed as

AsthmaSphingolipidsSteroidsBiomarkersDisease ProgressionFemaleHumansMass SpectrometryMetabolomicsBiomarkersSphingolipidsSteroids

Identifiers

PMID41554715
PMCPMC12815949

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.